Clozapine-induced myocarditis may be associated with rapid titration: A case report verified with autopsy

International Journal of Psychiatry in Medicine

Volumn 51, Issue 1, 2016, Pages 104-115

  Chopra, Nitin ^a   De Leon, Jose ^a,b,c,d  

^a UNIVERSITY OF KENTUCKY   (United States)

^b Eastern State Hospital   (United States)

^c UNIVERSITY OF GRANADA   (Spain)

^d UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Clozapine administration and dosage; Clozapine adverse effects; Lamotrigine; Mortality drug effects; Myocarditis chemically induced; Myocarditis etiology; Myocarditis pathology; Myocarditis prevention and control; Valproic acid

Indexed keywords

BENZATROPINE; CLOZAPINE; HYDROCHLOROTHIAZIDE; LAMOTRIGINE; LISINOPRIL; QUETIAPINE; VALPROATE SEMISODIUM; VALPROIC ACID; NEUROLEPTIC AGENT;

ADULT; ARTICLE; AUTOPSY; CASE REPORT; DRUG METABOLISM; DYSKINESIA; ELECTROCARDIOGRAPHY; EOSINOPHIL; HUMAN; HYPERTENSION; INCIDENCE; LYMPHOCYTIC INFILTRATION; MALE; MIDDLE AGED; MYOCARDITIS; POLYPHARMACY; SCHIZOAFFECTIVE PSYCHOSIS; SLEEP DISORDERED BREATHING; STEVENS JOHNSON SYNDROME; SUDDEN DEATH; CHEMICALLY INDUCED; FATALITY; PSYCHOTIC DISORDERS;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; FATAL OUTCOME; HUMANS; MALE; MIDDLE AGED; MYOCARDITIS; PSYCHOTIC DISORDERS;

EID: 84959118939     PISSN: 00912174     EISSN: 15413527     Source Type: Journal    
DOI: 10.1177/0091217415621269     Document Type: Article

References (34)

1. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382: 951-962.
2. Frogley C, Taylor D, Dickens G, et al. A systematic review of the evidence of cloza-pine's anti-aggressive effects. Int J Neuropsychopharmacol 2012; 15: 1351-1371.
3. Li XB, Tang YL, Wang CY, et al. Clozapine for treatment-resistant bipolar disorder: a systematic review. Bipolar Disord 2015; 17: 235-247.
4. Verghese C, de Leon J and Josiassen R. Problems and progress in the diagnosis and treatment of polydipsia and hyponatremia. Schizophr Bull 1996; 22: 455-464.
5. van Harten PN and Tenback DE. Tardive dyskinesia: clinical presentation and treatment. Int Rev Neurobiol 2011; 98: 187-210.
6. Seppi K, Weintraub D, Coelho M, et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011; 26(Suppl 3): S42-S80.
7. Cohen D. Prescribers fear as a major side-effect of clozapine. Acta Psychiatr Scand 2014; 130: 154-155.
8. Cohen D, Bogers J, van Dijk D, et al. Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. J Clin Psychiatry 2012; 73: 1307-1312.
9. Alawami M, Wasywich C, Cicovic A, et al. A systematic review of clozapine induced cardiomyopathy. Int J Cardiol 2014; 176: 315-320.
10. Merrill DB, Dec GW and Goff DC. Adverse cardiac effects associated with cloza-pine. J Clin Psychopharmacol 2005; 25: 32-41.
11. De Berardis D, Serroni N, Campanella D, et al. Update on the adverse effects of clozapine: focus on myocarditis. Curr Drug Saf 2012; 7: 55-62.
12. Ronaldson JK, Fitzgerald PB, Taylor AJ, et al. Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study. Schizophr Res 2012; 141: 173-178.
13. Ronaldson KJ, Taylor AJ, Fitzgerald PB, et al. Diagnostic characteristics of cloza-pine-induced myocarditis identified by an analysis of 38 cases and 47 controls. J Clin Psychiatry 2010; 71: 976-981.
14. Ronaldson KJ, Fitzgerald PB and McNeil JJ. Clozapine-induced myocarditis, a widely overlooked adverse reaction. Acta Psychiatr Scand 2015; 132: 231-240.
15. Freudenreich O. Clozapine-induced myocarditis: prescribe safely but do prescribe. Acta Psychiatr Scand 2015; 132: 240-241.
16. Hatton JL, Bhat PK and Gandhi S. Clozapine-induced myocarditis: recognizing a potentially fatal adverse reaction. Tex Heart Inst J 2015; 42: 155-157.
17. Kitulwatte ID, Kim PJH and Pollamen MS. Sudden death related myocarditis: a study of 56 cases. Forensic Sci, Med Pathol 2010; 6: 13-19.
18. Meeker JE, Herrmann PW, Som CW, et al. Clozapine tissue concentrations following an apparent suicidal overdose of Clozaril. J Anal Toxicol 1992; 16: 54-56.
19. Fineschi V, Neri M, Riezzo I, et al. Sudden cardiac death due to hypersensitivity myocarditis during clozapine treatment. Int J Legal Med 2004; 118: 307-309.
20. Gallagher RM, Kirkham JJ, Mason JR, et al. Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool. PLoS One 2011; 6: e28096.
21. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245.
22. Sabaawi M, Singh NN and de Leon J. Guidelines for the use of clozapine in individuals with developmental disabilities. Res Dev Disabil 2006; 27: 309-336.
23. Pui-yin Chung J, Shiu-yin Chong C, Chung KF, et al. The incidence and characteristics of clozapine-induced fever in a local psychiatric unit in Hong Kong. Can J Psychiatry 2008; 53: 857-862.
24. Diaz FJ, Santoro V, Spina E, et al. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry 2008; 41: 81-91.
25. Rajkumar AP, Poonkuzhali B, Kuruvilla A, et al. Clinical predictors of serum clo-zapine levels in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol 2013; 28: 50-56.
26. de Leon J. The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part I: a summary of the current state for clinicians. Rev Psiquiatr Salud Ment 2015; 8: 97-115.
27. Spina E and de Leon J. Clinical applications of CYP genotyping in psychiatry. J Neural Transm 2015; 122: 5-28.
28. Netherlands Clozapine Collaboration Group. Guideline for the use of clozapine. Version 05-02-2013. http://www.clozapinepluswerkgroep.nl/wp-content/uploads/ 2013/07/Guideline-for-the-use-of-Clozapine-2013.pdf Accessed May 3, 2015.
29. Ronaldson KJ, Fitzgerald PB, Taylor AJ, et al. A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. Aust N Z J Psychiatry 2011; 45: 458-465.
30. Munshi TA, Volochniouk D, Hassan T, et al. Clozapine-induced myocarditis: is mandatory monitoring warranted for its early recognition? Case Rep Psychiatry 2014; 2014: 513108.
31. de Leon J, Tang YL, Baptista T, et al. Titrating clozapine amidst recommendations proposing high myocarditis risk and rapid titrations. Acta Psychiatrica Scand 2015; 132: 242-243.
32. Wong IC, Mawer GW and Sander JW. Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother 1999; 33: 1037-1042.
33. Ketter TA, Greist JH, Graham JA, et al. The effect of dermatologic precautions on the incidence of rash with addition of lamotrigine in the treatment of bipolar I disorder: a randomized trial. J Clin Psychiatry 2006; 67: 400-406.
34. Calabrese JR, Sullivan JR, Bowden CL, et al. Rash in multicenter trials of lamotri-gine in mood disorders: clinical relevance and management. J Clin Psychiatry 2002; 63: 1012-1019.relevance and management. J Clin Psychiatry 2002; 63: 1012-1019.